Pharmacology of Dapagliflozin

Introduction/Overview

Dapagliflozin represents a significant advancement in the therapeutic management of type 2 diabetes mellitus and related cardiometabolic conditions. As a member of the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, its mechanism of action is distinct from all prior antidiabetic agents, offering a novel approach centered on urinary glucose excretion. The clinical relevance of dapagliflozin extends beyond glycemic control, encompassing demonstrated benefits in cardiovascular and renal outcomes, which has reshaped treatment guidelines for high-risk patient populations. Its introduction marked a paradigm shift from a purely glucocentric treatment strategy to one addressing broader cardiorenal risk.

The importance of understanding dapagliflozin’s pharmacology is underscored by its expanding list of approved indications and its prominent position in contemporary treatment algorithms. Mastery of its pharmacokinetic profile, mechanism, and adverse effect spectrum is essential for safe and effective clinical application across multiple therapeutic areas, including endocrinology, cardiology, and nephrology.

Learning Objectives

• Describe the molecular mechanism of action of dapagliflozin as a selective SGLT2 inhibitor and its consequent physiological effects.
• Outline the pharmacokinetic properties of dapagliflozin, including absorption, distribution, metabolism, excretion, and key dosing considerations.
• Identify the approved therapeutic indications for dapagliflozin, including type 2 diabetes, heart failure, and chronic kidney disease, and explain the evidence supporting these uses.
• Analyze the common and serious adverse effects associated with dapagliflozin therapy, with particular attention to genitourinary infections, euglycemic diabetic ketoacidosis, and volume depletion.
• Evaluate clinically significant drug interactions, contraindications, and special population considerations pertinent to dapagliflozin prescribing.

Classification

Dapagliflozin is classified primarily as an antidiabetic agent. Its specific categorization is as a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This class is also referred to as gliflozins. Within this class, dapagliflozin was among the first agents approved for clinical use in many jurisdictions and is characterized by its high selectivity for the SGLT2 transporter over the related SGLT1 isoform.

Chemical Classification

Chemically, dapagliflozin is a C-aryl glucoside derivative. Its systematic name is (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol. The molecular structure features a glucose-like moiety linked to a diarylmethane group, which is crucial for its binding affinity and selectivity for the SGLT2 protein. This structure is distinct from endogenous glucose, allowing it to competitively inhibit the transporter without being metabolized. The compound is typically administered as the propanediol monohydrate (dapagliflozin propanediol) in its pharmaceutical formulation.

Mechanism of Action

The pharmacodynamic profile of dapagliflozin is defined by its primary and secondary mechanisms, which collectively confer its therapeutic benefits.

Primary Pharmacodynamics: SGLT2 Inhibition

Dapagliflozin functions as a potent, competitive, and highly selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). SGLT2 is a high-capacity, low-affinity transporter located almost exclusively in the S1 segment of the proximal convoluted tubule of the nephron. Under normal physiological conditions, SGLT2 is responsible for the reabsorption of approximately 90% of the filtered glucose load from the glomerular filtrate back into the systemic circulation. This reabsorption is an active process coupled to sodium transport, utilizing the sodium gradient established by Na+/K+ ATPase pumps on the basolateral membrane.

By binding reversibly to SGLT2, dapagliflozin blocks this reabsorptive capacity. This inhibition results in glucosuria, as glucose remains in the tubular lumen and is excreted in the urine. The amount of glucose excreted is directly proportional to the plasma glucose concentration and the glomerular filtration rate, typically ranging from 60 to 80 grams per day at therapeutic doses. This mechanism is independent of insulin secretion or sensitivity, distinguishing it from other antidiabetic drug classes.

Molecular and Cellular Mechanisms

At the molecular level, dapagliflozin competes with glucose for binding to the SGLT2 protein. The drug’s affinity for SGLT2 is significantly higher than that of glucose, with an inhibitory constant (K_i) in the low nanomolar range. Its selectivity ratio for SGLT2 over SGLT1 is greater than 1,200-fold. SGLT1, located in the S3 segment of the proximal tubule and the intestinal mucosa, is responsible for reabsorbing the remaining 10% of filtered glucose and for dietary glucose absorption. The high selectivity minimizes gastrointestinal side effects related to SGLT1 inhibition, such as osmotic diarrhea.

The cellular consequences of SGLT2 inhibition extend beyond simple glucosuria. The increased delivery of sodium to the distal tubule activates tubuloglomerular feedback, leading to afferent arteriolar constriction. This reduces intraglomerular pressure and glomerular filtration rate (GFR), an effect believed to contribute to the drug’s renoprotective properties. Furthermore, the loss of calories via glucosuria induces mild weight loss, primarily from reduced adipose tissue mass.

Secondary Physiological Effects

The primary action of inducing glucosuria sets in motion several secondary physiological effects that underpin the drug’s expanded clinical benefits:

• Hemodynamic Effects: The mild natriuresis and osmotic diuresis caused by glucosuria lead to a reduction in plasma volume, preload, and blood pressure. This hemodynamic unloading of the heart is a key component of its benefit in heart failure.
• Metabolic Effects: Beyond lowering plasma glucose, chronic SGLT2 inhibition may shift substrate utilization. There is evidence suggesting increased lipolysis and a modest shift towards ketone body production as an energy source, which necessitates monitoring for euglycemic ketoacidosis.
• Cardiac and Renal Effects: The reduction in intraglomerular pressure, combined with possible direct anti-inflammatory and antifibrotic effects on renal and cardiac tissue, contributes to organ protection. These effects appear to be partly independent of glycemic control.
• Electrolyte Changes: Mild increases in serum magnesium and phosphate may occur, while serum uric acid levels typically decrease due to increased urinary excretion.

Pharmacokinetics

The pharmacokinetic profile of dapagliflozin is characterized by predictable absorption, extensive metabolism, and renal elimination of metabolites, with properties that support once-daily dosing.

Absorption

Following oral administration, dapagliflozin is rapidly absorbed from the gastrointestinal tract. The absolute oral bioavailability is estimated to be approximately 78%. The time to reach peak plasma concentration (t_max) is generally within 2 hours under fasting conditions. Food intake does not significantly alter the overall extent of absorption (AUC), but it may delay t_max by approximately 1 hour and lower the peak plasma concentration (C_max) by up to 50%. This effect is not considered clinically significant, and dapagliflozin can be administered with or without food.

Distribution

Dapagliflozin demonstrates extensive tissue distribution. The steady-state volume of distribution is approximately 118 liters, indicating distribution well beyond plasma volume. In vitro plasma protein binding is high, at about 91%, primarily to albumin. The drug’s distribution into red blood cells is limited. The extent of distribution is not significantly altered by age, body weight, sex, or the presence of type 2 diabetes.

Metabolism

Dapagliflozin undergoes extensive hepatic metabolism, primarily via uridine diphosphate-glucuronosyltransferase (UGT) enzymes, specifically UGT1A9. This Phase II conjugation reaction produces dapagliflozin 3-O-glucuronide as the major inactive metabolite. Minor oxidative pathways mediated by cytochrome P450 enzymes are also involved but to a much lesser extent. The major metabolite possesses negligible pharmacological activity against SGLT2, accounting for less than 10% of the parent drug’s potency. The extensive first-pass metabolism contributes to the drug’s predictable systemic exposure.

Excretion

Elimination occurs predominantly via renal and biliary routes. Following metabolism, approximately 75% of the administered dose is excreted in the urine, primarily as the inactive glucuronide metabolite. Less than 2% of the dose is recovered in urine as unchanged parent drug. About 21% of the dose is excreted in the feces, largely as metabolites. The total body clearance of dapagliflozin is estimated to be 200 mL/min. The terminal elimination half-life (t_1/2) of dapagliflozin is approximately 12.9 hours, which supports once-daily dosing. Steady-state concentrations are achieved within 3 to 5 days of repeated dosing.

Dosing Considerations

The recommended starting dose for most indications is 10 mg once daily, administered orally. A 5 mg once-daily dose is also available and may be used for tolerability or in specific populations. Dosing is not typically adjusted for food intake. In patients with type 2 diabetes, the glucose-lowering effect is observed within the first day of treatment, with maximal glycemic efficacy attained within 1 to 2 weeks. The pharmacokinetics are linear and dose-proportional over the therapeutic dose range.

Therapeutic Uses/Clinical Applications

Dapagliflozin has received regulatory approval for several indications based on large-scale cardiovascular and renal outcome trials, reflecting its pleiotropic benefits.

Approved Indications

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is used as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, DPP-4 inhibitors, insulin, and GLP-1 receptor agonists. Its efficacy in lowering HbA1c is typically in the range of 0.5% to 0.8%.
• Heart Failure with Reduced Ejection Fraction (HFrEF): To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (NYHA class II-IV), regardless of the presence of type 2 diabetes. This indication is supported by the DAPA-HF trial, which demonstrated a significant reduction in the composite endpoint of worsening heart failure or cardiovascular death.
• Heart Failure with Mildly Reduced or Preserved Ejection Fraction (HFmrEF/HFpEF): To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure. This broad indication, encompassing HFmrEF and HFpEF, is based on the DELIVER trial.
• Chronic Kidney Disease (CKD): To reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease who are at risk of progression, with or without type 2 diabetes. The DAPA-CKD trial established efficacy in patients with an eGFR of 25 to 75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio (UACR) of 200 to 5000 mg/g.

Off-Label Uses

While not formally approved, dapagliflozin is sometimes used or investigated in other contexts. These include polycystic ovary syndrome (PCOS) for metabolic improvements, and as part of a multifaceted approach in patients with obesity and type 2 diabetes for its weight loss effect. Its use in type 1 diabetes remains investigational and is not recommended outside of clinical trials due to a markedly increased risk of diabetic ketoacidosis.

Adverse Effects

The adverse effect profile of dapagliflozin is largely predictable from its mechanism of action, with most events being mild to moderate in severity.

Common Side Effects

• Genitourinary Infections: The increased glucose concentration in the urinary tract creates a favorable environment for microbial growth. Genital mycotic infections (e.g., vulvovaginal candidiasis, balanitis) are among the most frequently reported adverse events, occurring more commonly in females, uncircumcised males, and patients with a prior history of such infections. Urinary tract infections, including pyelonephritis and urosepsis, may also occur at a slightly higher incidence compared to placebo.
• Volume Depletion-Related Effects: The osmotic diuretic effect can lead to reduced intravascular volume, manifesting as symptomatic hypotension, dizziness, orthostatic hypotension, and syncope. Dehydration and increased thirst are also reported. The risk is heightened in the elderly, patients on diuretics, and those with low systolic blood pressure or impaired renal function.
• Increased Urination: Polyuria and pollakiuria are common, especially during initial therapy, as a direct result of glucosuria.
• Laboratory Abnormalities: Small increases in serum creatinine (≈0.1-0.2 mg/dL) and corresponding decreases in eGFR are often observed upon initiation, reflecting the hemodynamic effect on the glomerulus. These changes are usually transient and reversible upon discontinuation. Increases in serum phosphate, magnesium, and low-density lipoprotein cholesterol (LDL-C) may also be noted.

Serious/Rare Adverse Reactions

• Euglycemic Diabetic Ketoacidosis (euDKA): This is a potentially life-threatening metabolic acidosis characterized by elevated anion gap, ketonemia, and ketonuria, but with blood glucose levels often below 250 mg/dL. The risk is increased in conditions of insulin deficiency (e.g., type 1 diabetes, latent autoimmune diabetes in adults, post-pancreatectomy), during prolonged fasting, acute illness, surgery, or excessive alcohol intake. The mechanism involves a combination of reduced insulin secretion, increased glucagon, and enhanced renal ketone reabsorption.
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): A rare but serious, life-threatening necrotizing infection of the perineum and genital region has been reported in patients taking SGLT2 inhibitors, including dapagliflozin. This requires urgent surgical debridement and broad-spectrum antibiotics.
• Lower Limb Amputation: Data from a trial with a related SGLT2 inhibitor suggested a potential increased risk of lower limb amputations, primarily toes. While the signal was not confirmed in the major dapagliflozin outcome trials (DAPA-HF, DAPA-CKD), caution is advised in patients with prior amputation, peripheral arterial disease, neuropathy, or diabetic foot ulcers.
• Acute Kidney Injury: Cases of acute kidney injury, sometimes requiring hospitalization and dialysis, have been reported. This risk may be precipitated by volume depletion, concomitant use of diuretics, NSAIDs, or ACE inhibitors/ARBs, and pre-existing renal impairment.
• Ketoacidosis in Type 1 Diabetes: The use in type 1 diabetes is contraindicated due to a very high risk of diabetic ketoacidosis.
• Serious Urinary Tract Infections: Including urosepsis and pyelonephritis.
• Hypersensitivity Reactions: Angioedema and anaphylactic reactions have been reported rarely.

Black Box Warnings

Dapagliflozin carries a boxed warning regarding the risk of euglycemic diabetic ketoacidosis. This warning emphasizes that ketoacidosis may be present even with blood glucose levels below 250 mg/dL, necessitating a high index of suspicion. It advises assessing for ketoacidosis in patients presenting with symptoms of metabolic acidosis (e.g., nausea, vomiting, abdominal pain, malaise, dyspnea) regardless of blood glucose level, and to discontinue dapagliflozin if ketoacidosis is suspected.

Drug Interactions

Dapagliflozin has a relatively low potential for pharmacokinetic drug-drug interactions due to its metabolism primarily by UGT enzymes and low involvement of cytochrome P450 systems. However, pharmacodynamic interactions are more common and clinically significant.

Major Drug-Drug Interactions

• Diuretics (Loop and Thiazide): Concomitant use increases the risk of volume depletion, symptomatic hypotension, and acute kidney injury due to additive diuretic effects. Blood pressure, volume status, and renal function should be monitored closely, especially during initiation.
• Insulin and Insulin Secretagogues (Sulfonylureas, Meglitinides): The glucose-lowering effects of dapagliflozin are additive to those of insulin and insulin secretagogues. This combination increases the risk of hypoglycemia. A reduction in the dose of insulin or the secretagogue may be required to mitigate this risk.
• Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Blockers (ARBs): While often used together for cardiorenal protection, this combination can potentiate the risk of hypotension and acute kidney injury, particularly in volume-depleted patients or those with renal artery stenosis.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs may attenuate the diuretic and natriuretic effect of dapagliflozin and, more importantly, can impair renal autoregulation, increasing the risk of acute kidney injury, especially in the setting of volume depletion.
• Other SGLT2 Inhibitors: Concomitant use with another SGLT2 inhibitor is contraindicated due to the lack of additive efficacy and increased risk of adverse effects.
• Drugs that Induce UGT Enzymes: Strong inducers of UGT1A9 (e.g., rifampin, phenytoin, ritonavir) may increase the metabolism of dapagliflozin, potentially reducing its plasma concentration and efficacy. Monitoring of glycemic control is advised if such drugs are initiated or discontinued.

Contraindications

• History of serious hypersensitivity reaction to dapagliflozin or any product component.
• Patients with type 1 diabetes mellitus.
• Patients with a history of diabetic ketoacidosis.
• Severe renal impairment (eGFR persistently below 25 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis, for the treatment of type 2 diabetes. For the heart failure and CKD indications, specific eGFR thresholds apply as per trial criteria.

Special Considerations

Use in Pregnancy and Lactation

Pregnancy: Dapagliflozin is not recommended during the second and third trimesters of pregnancy. Data from animal studies have shown renal pelvic and tubule dilatation in offspring when dams were exposed during a period corresponding to the late second and third trimesters in humans. There are no adequate and well-controlled studies in pregnant women. Because of the potential for adverse effects on renal development, use during pregnancy, especially beyond the first trimester, should be avoided. The drug is classified as Pregnancy Category C (under the former FDA classification system).

Lactation: It is not known whether dapagliflozin is excreted in human milk. Data from animal studies indicate that dapagliflozin and its metabolites are present in rat milk. Given the potential for serious adverse reactions in nursing infants from SGLT2 inhibitors, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric and Geriatric Considerations

Pediatric: The safety and efficacy of dapagliflozin in pediatric patients (under 18 years of age) have not been established. Its use is not approved in this population.

Geriatric: No dosage adjustment is recommended based solely on age. However, elderly patients (≥65 years) are more likely to have impaired renal function and may be more sensitive to the volume-depleting effects of the drug, leading to a higher incidence of adverse reactions related to volume depletion (e.g., hypotension, dizziness, syncope, renal impairment). Renal function should be assessed prior to initiation and monitored periodically.

Renal Impairment

Renal function significantly impacts the efficacy and safety profile of dapagliflozin. The glucose-lowering effect is dependent on filtered glucose load; thus, efficacy diminishes as renal function declines.

• For Type 2 Diabetes: The drug is effective when eGFR is ≥45 mL/min/1.73 m². When eGFR is persistently between 25 and 45 mL/min/1.73 m², the glycemic efficacy is reduced. It is not recommended to initiate therapy for diabetes if eGFR is below 45 mL/min/1.73 m² and is contraindicated when eGFR is persistently below 25 mL/min/1.73 m² or in patients on dialysis.
• For Heart Failure and CKD: The indications are based on specific renal function criteria from clinical trials. For heart failure, it can be initiated with an eGFR ≥25 mL/min/1.73 m². For CKD, the indication is for patients with an eGFR 25 to 75 mL/min/1.73 m² and significant albuminuria (UACR ≥200 mg/g). Dose interruption is recommended if eGFR falls below 25 mL/min/1.73 m² during treatment for these indications, with potential re-initiation if eGFR improves.
• Renal function should be assessed prior to initiation and monitored regularly thereafter, especially in patients with eGFR below 60 mL/min/1.73 m².

Hepatic Impairment

No dosage adjustment is recommended for patients with mild or moderate hepatic impairment (Child-Pugh classes A and B). The pharmacokinetics of dapagliflozin in patients with severe hepatic impairment (Child-Pugh class C) have not been studied. Use in this population is not recommended due to the lack of data and potential for increased systemic exposure from reduced metabolic capacity.

Summary/Key Points

• Dapagliflozin is a highly selective, competitive inhibitor of the sodium-glucose cotransporter 2 (SGLT2) in the renal proximal tubule, leading to urinary glucose excretion and a consequent reduction in plasma glucose levels.
• Its mechanism confers multiple physiological benefits beyond glycemic control, including osmotic diuresis, mild natriuresis, weight loss, blood pressure reduction, and hemodynamic effects that contribute to cardiorenal protection.
• Pharmacokinetically, it is well-absorbed, highly protein-bound, extensively metabolized via UGT1A9 to inactive metabolites, and eliminated renally, with a half-life supporting once-daily dosing.
• Approved indications now extend beyond type 2 diabetes to include heart failure (HFrEF, HFmrEF, and HFpEF) and chronic kidney disease in at-risk patients, based on robust outcome trial data.
• The most common adverse effects are genitourinary infections and volume depletion-related events. Serious risks include euglycemic diabetic ketoacidosis (carrying a boxed warning), necrotizing fasciitis of the perineum, and acute kidney injury.
• Significant pharmacodynamic interactions exist with diuretics, insulin, and insulin secretagogues (increased hypoglycemia and volume depletion risk). It is contraindicated in type 1 diabetes, severe renal impairment for glycemic control, and in patients with a history of serious hypersensitivity.
• Special caution is required in the elderly, those with renal impairment, and during volume-depleted states. It is not recommended in the second and third trimesters of pregnancy or during lactation.

Clinical Pearls

• Monitor for signs of euglycemic DKA (nausea, vomiting, abdominal pain) even with normal or mildly elevated blood glucose, especially during acute illness, surgery, or reduced oral intake. Check ketones if suspected.
• Assess renal function (eGFR) prior to initiation and periodically thereafter. The initial dip in eGFR is often hemodynamic and reversible but requires monitoring.
• Counsel patients on the increased risk of genital mycotic infections and advise on preventive hygiene measures. Also, advise on maintaining adequate hydration to mitigate volume depletion risk.
• For patients with heart failure or CKD, the benefits on hospitalization and mortality/progression are largely independent of diabetes status. Consider these indications in eligible patients regardless of HbA1c.
• When adding dapagliflozin to insulin or a sulfonylurea, proactively consider reducing the dose of the concomitant agent to prevent hypoglycemia.
• Discontinue dapagliflozin at least 3-4 days prior to elective surgery or procedures that require fasting to reduce the risk of perioperative ketoacidosis.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.